EKLF gene study in beta-thalassemia
Part of Blood & lymphatic clinical trials.
This study looks at a gene called EKLF in people with beta-thalassemia. It aims to understand how this gene works in the body, which could help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with beta-thalassemia (either major or intermedia, which are the more common forms).
- You can be male or female at any age.
- You cannot have any other type of hemolytic anemia (a condition that also destroys red blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This trial tests if certain drugs can safely increase fetal hemoglobin (a type of hemoglobin that helps carry oxygen) in people with beta thalassemia major. It may offer a new way to manage the condition and reduce the need for transfusions.
This study looks for changes in a specific gene (KLF1) that might be linked to beta-thalassemia. If you have beta-thalassemia, joining could help researchers understand the disease better — and it involves only a blood test for DNA analysis.
This trial tests a new gene-editing treatment called CS-101 for people with beta-thalassemia major who need regular blood transfusions. It aims to see if the treatment is safe and can reduce or eliminate the need for transfusions.
Hear when a new Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.